Ivabradine in Patients With Congestive Heart Failure

• Status: Completed
• Trial end date: 2021-02-05
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to assess the efficacy of Ivabradine therapy in patients with congestive heart failure using the cardiac biomarkers NT-Pro BNP and Neopterin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University

Criteria

Inclusion Criteria:

• Patients with chronic HF, on optimized medical therapy according to European Society of Cardiol¬ogy guidelines, with LV ejection fraction (LVEF) < 35% according to the Simpson method, New York Heart Association (NYHA) class II-III, and sinus rhythm and resting HR > 70/min were eligible for inclusion in the study.

Exclusion Criteria:

• acute decompen¬sation (acute coronary syndromes and acute HF);

• hemodynamically significant valve disease;

• cer¬ebrovascular events during the previous 6 months;

• dysfunctional prosthetic heart valve;

• obstructive or non-obstructive cardiomyopathy; uncorrected congenital heart disease; active myocarditis;

• a his¬tory of resuscitation from sudden death; an absence of stable sinus rhythm, severe arrhythmias; HR < 60 bpm; sick sinus syndrome; second-degree and third-degree atrioventricular block;

• severe obesity (body mass index > 36 kg/m²);

• established or sus¬pected pulmonary diseases (vital capacity < 80% or forced expiratory volume in 1 s < 80% of age spe¬cific and sex-specific reference values);

• hemoglobin ≤ 11 g/dL;

• treatment with non-dihydropyridine calcium-channel blockers, class I antiarrhythmic agents, strong inhibitors of cytochrome P450-3A4, or QT interval-prolonging medications;

• acute and chronic kidney failure;

• pregnancy; hypo- and hy¬perthyroidism or acute infections.